Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

GSK Gains European Approval for Combination Antiretroviral Drug Kivexa

December 23, 2004

GlaxoSmithKline on Wednesday announced that it has received marketing approval from the European Commission for its antiretroviral drug Kivexa, which is a once-a-day tablet that combines the company's Epivir and Ziagen, known generically as lamivudine and abacavir, respectively, Reuters reports. Kivexa has no food or fluid restrictions, according to Reuters. Studies have shown that patients taking antiretrovirals more easily adhere to drug regimens when there are no food or fluid restrictions (Reuters, 12/22). "Kivexa is an important advance in GSK's ongoing commitment to provide new options in antiretroviral therapy for HIV patients," Didier Lapierre, vice president of infectious diseases at GSK, said, adding, "Kivexa will provide clinicians and HIV-infected patients with a flexible, well-tolerated and potent combination of the two [nucleoside reverse transcriptase inhibitors] that have been widely used in antiretroviral therapy for years. Prescribers are familiar with these medications, which have an established resistance and long-term safety profile" (GSK release, 12/22).

Back to other news for December 23, 2004


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More HIV News

Tools
 

Advertisement